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MICRODELETIONS AFFECTING THE GNAS LOCUS IN 
PSEUDOHYPOPARATHYROIDISM: CHARACTERIZATION OF THE 
UNDERLYING MECHANISMS 
 
 
INTRODUCTION 
 
Pseudohypoparathyroidism type Ia (PHP1A, MIM#103580) is a rare genetic disorder, 
whose hallmark is end-organ resistance to parathyroid hormone (PTH) due to partial 
deficiency of the alpha subunit of the stimulatory G protein (Gsα), encoded by the 
complex imprinted GNAS locus (MIM#139320). PHP1A patients are characterized by 
PTH resistance, defined as raised serum PTH levels in the presence of hypocalcemia 
and hyperphosphatemia, and show features of obesity, mental retardation and Albright 
hereditary osteodystrophy (AHO) (1). PHP1A patients may also develop resistance to 
thyroid-stimulating hormone (TSH), gonadotropins and growth-hormone-releasing 
hormone (GHRH) (2, 3).  
 
The disease is inherited in an autosomal dominant manner and, generally, is caused by 
heterozygous maternally-derived inactivating mutations of Gsα coding exons (1, 4). 
This pattern of inheritance is consistent with Gsα tissue-specific imprinting and its 
predominant maternal expression has been indeed demonstrated in specific human 
tissues, comprising proximal renal tubules, pituitary, gonads, and thyroid (5).  
 
In 1990, Patten et al. described the first GNAS loss-of-function mutation responsible for 
PHP1A (4) and, to date, numerous different Gsα-coding mutations have been identified, 
with a detection rate of about 70% (1, 6 and personal data). Most defects are private 
mutations and few recurrent mutations in unrelated patients probably derived from the 
presence of a common molecular mechanism rather than a founder effect (7). The 
detection of a mutation is associated with the development of the disease and 50% of 
occurrence in the offspring, thus the genetic test provides a diagnosis together with the 
possibility of genetic counseling in relatives.  
Nevertheless, the molecular determinants of 30% patients still remains unclear and, in 
the last years, different papers described GNAS epigenetic defects, similar to those 
classically found in PHP−Ib patients, in a subset of patients with PHP and variable 
degrees of AHO, suggesting a molecular overlap between PHP1A and PHP1B (8).  
 
Recently, some cases of PHP1A patients with deletions of 20q, including part or the 
whole GNAS gene, and an inversion at GNAS were reported, demonstrating that 
chromosomal rearrangements may also cause PHP1A and that investigation for these 
less common genetic defects is needed (9). Moreover, deletions ablating GNAS DMRs 
mimic an imprinting defect during the methylation analysis and may lead to a 
misdiagnosis of PHP1B (10). These defects, undetectable by Sanger sequencing and 
often also by karyotype investigation, are considered clearly distinct from the small-
scale gene mutations, both for the size of the rearranged DNA and the underlying 
formation mechanisms (11, 12). 
 
In order to ameliorate molecular diagnostic and genetic counseling, the aims of our 
work were to identify and characterize novel GNAS locus defects, such as micro-
deletions or –duplications, associated with PHP1A/PPHP using methylation specific-
multiplex ligation-dependent probe amplification (MS-MLPA) and custom made CGH 
array and unravel putative molecular mechanisms responsible for these rearrangements.  
 
PATIENTS AND METHODS 
 
A total of 112 patients with PHP1A/PPHP phenotype and no GNAS mutations, all born 
from non-consanguineous parents, were studied. The clinical diagnosis was based upon 
the presence of at least two of the six AHO manifestations: brachydactyly (shortening of 
fourth and/or fifth metacarpals), short stature (height below the 3th percentile for 
chronological age), obesity (BMI >30 kg/m2 in adults and >97th centile in children), 
round face, subcutaneous ossifications (either clinically evident or at X-ray), and mental 
retardation; when these signs were observed in the presence of PTH resistance (i.e. 
hypocalcemia, hyperphosphatemia and raised serum PTH levels), PHP1A diagnosis was 
made. All PHP1A patients showed also resistance to TSH, documented by raised serum 
TSH levels, absence of anti-thyroid antibodies and presence of a normal thyroid scan.  
Patients were studied in different labs, using different techniques. A detailed description 
of methods is provided as supplementary data (point 1, Supp.Table 1). Informed consent 
was obtained from all patients and relatives included in the study. 
 
RESULTS 
 
Allele dosage and methylation analysis by MS-MLPA or custom aCGH revealed the 
presence of 7 heterozygous deletions of part or whole GNAS locus,  ranging from 106-
bp to 2.6-Mb, in a cohort of 112 GNAS point mutation-negative PHP1A/PPHP 
probands (detection rate 6.25%).   
Six of the seven patients (2 females and 4 males) were affected by PHP1A, and one 
female patient by PPHP (patient #6). When possible, the parental origin of the deletion 
was identified and the whole family studied. Main clinical features of deleted patients 
and affected relatives are described in Table 1. A comprehensive description of novel 
rearrangements is available in the supplementary data section 2 (Figure 1A/B). 
Deletions’ breakpoints were subjected to bioinformatic analyses to explore underlying 
mechanisms and to assess the contribution of the genomic architecture. We analyzed the 
extent of microhomology at breakpoints and investigated for the presence of known 
sequence motifs, purine-pyrimidine repeats, AT-content and repetitive elements. An 
overview of all these results can be found in supplementary data point 3 (Supp.Table 2).  
 
DISCUSSION 
 
In about 70% of cases, PHP1A/PPHP are due to haploinsufficiency caused by 
maternally/paternally-inherited heterozygous inactivating mutations of the GNAS gene 
(1, 6). A subset of patients not carrying mutations in GNAS coding exons might have a 
deletion removing the entire or part of the GNAS gene. Constitutional aberrations of the 
long arm of chromosome 20 are quite rare, and, to our knowledge, only 7 cases with an 
interstitial chromosome 20q deletion including GNAS have been described in the 
literature so far (9, 10, 13 - 15).  
 
Here, we report 1 PPHP and 6 PHP1A patients with different submicroscopic deletions 
including part or the whole GNAS locus. Accordingly, we describe novel deletions in 
7/112 probands (6.25%), confirming that these events represent a significant cause of 
PPHP/PHP1A, and that, although undetectable by standard PCR-based sequencing, they 
can be clearly identified by aCGH or MS-MLPA. 
For a subset of PHP patients, for whom no mutations are identified by GNAS coding 
region sequencing, the presence of a deletion should be considered for a proper genetic 
counseling. Indeed, some patients studied for the presence of imprinting defects by 
methylation-quantitative techniques could be misdiagnosed as PHP1B patients, as 
previously indicated (10) and now confirmed by patients #1 and #5 of the present work. 
Unfortunately, a deep phenotypic characterization does not allow to clearly identify a 
priori the causative molecular defect.  
 
Our findings suggest that some clinical features, namely mental retardation, short 
stature, round face, brachydactyly, subcutaneous ossifications, are common to most 
patients, as expected by the removal of GNAS Gsα-coding exons. As for the PHP1A 
phenotype in particular, in accordance with previously reported series showing no 
genotype/phenotype correlation in this disease (7, 16), in this cohort there is no apparent 
clinical difference between patients with point mutations and those with GNAS 
deletions. Moreover, as described for point mutations, intrafamilial differences in 
phenotypic expression can also be found in those with GNAS rearrangements and be not 
only associated to the imprinting effect (family #2 and #7 of the present report, 13). 
 
Hyperinsulinemia, namely reduced insulin sensitivity, and type 2 diabetes have been 
recently identified as an additional feature of adult PHP1A (17). On the contrary, 
complex phenotypes (attention deficit disorder, Evans syndrome, cirrhosis, psoriasis, 
asthma and bilateral adrenal hyperplasia) may result from a contiguous gene deletion 
syndrome, as they are hardly explained by GNAS haploinsufficiency alone. We 
compared our cases with those previously described by 2 other groups and determined 
the smallest region of overlap (SRO) among deletions, in order to unveil genes 
contributing to common and, symmetrically, patient-specific clinical features (9, 1528) 
(Supp.Figure 1). Patients with a paternal deletion suffered from pre- and post- natal 
severe growth retardation, dysmorphism, hypotonia and feeding difficulties, but no 
further similarities can be deduced as 2 cases, with no typical AHO phenotype, were too 
young and could have developed other signs over the time. As for maternal deletions, 
there aren’t significant differences in involved genes that might explain the reported 
clinical differences. However, the number of patients with large deletions is too small to 
speculate the contribution of specific adjacent genes in determining complex 
phenotypes.  
Single or multi-exon rearrangements in GNAS can be routinely screened by MS-MLPA 
or aCGH (10, 18). However, these diagnostic techniques do not provide detailed 
information on breakpoints location, so different deletions involving the same exon(s) 
cannot be distinguished, nor can insight be acquired into the developmental mechanism 
of these rearrangements. Therefore, we have molecularly characterized the precise 
deletion boundaries in 5 of the 7 probands and hypothesized the developmental 
mechanism of these rearrangements. 
Genomic deletions can occur during the repair of DNA double strand breaks (DSB’s) by 
several mechanisms: (i) non-replicative repair mechanisms: non-homologous end-
joining (NHEJ) or non-allelic homologous recombination (NAHR) and (ii) replicative-
based repair mechanisms (19).  
The major DNA-repair mechanism in humans is NHEJ, either classical with short 
terminal microhomologies of no more than 4 bp, or non-classical (microhomology-
mediated end-joining - MMEJ). The insertion of additional bases at the breakpoint 
junction, as in patient #7, is a phenomenon associated to classical NHEJ, which is thus 
one potential mechanism for this deletion (19). 
NAHR, the most common mechanism underlying disease-associated genomic 
rearrangements and recurrent deletions, occurs between nonallelic homologous 
sequences, generally repetitive elements of at least 200-bp, such as long or short 
interspersed nuclear elements (LINE’s or SINE’s, including Alu-elements) or low copy 
repeats (LCR’s). Diverse studies demonstrated that an high content of Alu-elements 
results in increased frequency of gene disruption by large deletions in several human 
diseases, also called Alu-recombination mediated deletion (ARMD)-events (20). We 
analyzed the regions deleted in our patients for the presence of any of these elements 
and we found repetitive elements of the same family at both breakpoints in 4 cases  
(patient #1, #2, #6 and #7), which could indicate NAHR as causative mechanism. 
Therefore, an Alu-mediated NAHR might result in deletions of patients #2, #6 and #7, 
while patient #1 showed LINE2 elements at proximal and distal breakpoint junctions.  
Alternative mechanisms (NHEJ) appear to be involved in patient #4 deletion, as no 
repetitive elements were found in the proximity of the breakpoints. The most plausible 
cause for the deletion of patient #1 is a replicative-based repair mechanism, even though 
the presence of 2-bp microhomology at the breakpoint junction and deletion-associated 
DNA sequence motif at the proximal region could also be consistent with classical 
NHEJ.  
Overall, although each deletion event appears to be unique, Alu sequences play a major 
role in determining the instability of the region. Regardless of the specific 
recombination mechanism, genomic architectural features have been associated with 
many rearrangement breakpoints. This suggests that chromosomal rearrangements are 
not random events, but result from a predisposition due to the existence of a complex 
underlying genomic architecture that may create instability in the genome. 
In conclusion, our data confirm that GNAS deletions must be considered as a possible 
and significant cause of PPHP/PHP1A. In order to avoid misdiagnosis with PHP1B and 
to determine the recurrence risk in the offspring, patients negative for point mutations 
should be further investigated for such rare genetic defects. 
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Table 1: Clinical characteristics and molecular analysis of patients included in the present study 
Pt Sex 
Age Age PTH TSH 
Obesity AHO features 
Additional 
features 
Deletion extension Deleted Genes 
1 2 pg/ml mUI/L 
1 M 8 4 206 4.36 Yes Br/RF/SO/MR Hyperinsulinemia g. 57,224,346_59,795,557del  
STX16, NPEPL1, GNAS-AS1, GNAS, NELFCD, 
CTSZ, TUBB1, SLMO2, ATP5E, ZNF831, EDN3, 
PHACTR3, SYCP2, PPP1R3D, CDH26 
2a F 10 0.5 600 14 Yes Br/RF/MR - g.57,482,794_57,488,635del exon 7_exon 13 of GNAS 
2b F 8 0.2 88.3 12.44 No Br/SO - g.57,482,794_57,488,635del exon 7_exon 13 of GNAS 
3 M 15 16 342 17.7 No Br/SS/RF/MR - g.(57,463,738_57,464,100)_(57,466,893_57,470,666)del exon AB_exon 1 of GNAS 
4 M 40 0.6 312 ↑ No Br/SS/RF/SO 
Ankylosing 
spondilitis 
g.57,485,647_57,485,751del intron 12_exon 13 of GNAS 
5 M 19 2 478 ↑ Yes SS/SO/MR 
Attention deficit 
disorder, type 2 
diabetes, Evans 
syndrome, 
cirrhosis, 
psoriasis, asthma 
g.?-56,987,684_59,350,455del 
VAPB, APCDD1L, APCDD1L-AS1, STX16, 
NPEPL1, GNAS-AS1, GNAS, NELFCD, CTSZ, 
TUBB1, SLMO2, ATP5E, ZNF831, EDN3, 
PHACTR3, SYCP2, PPP1R3D, CDH26 
6 F 6 20 21 0.70 Yes Br/SS 
Bilateral adrenal 
hyperplasia 
g.55,926,305_57,675,815del 
MTRNR2L3, RBM38, CTCFL, PCK1, ZBP1, 
PMEPA1, PPP4R1L, RAB22A, VAPB, APCDD1L, 
APCDD1L-AS1, STX16, NPEPL1, GNAS-AS1, 
GNAS, NELFCD, CTSZ, TUBB1, SLMO2, ATP5E 
and putatively RAE1at the 5'end. 
7a F 1 0.5 277 27 Yes SS/SO/RF/MR Craniosynostosis g.57,475,484_57,481,914del intron 2_exon 6 of GNAS 
7b F 27 
 
120 6 No SS/SO/MR 
 
g.57,475,484_57,481,914del intron 2_exon 6 of GNAS 
  
Legend: Female (F), Male (M), Brachydactyly, clinically evident (Br), Short Stature (SS), Round Face (RF), Obesity was defined as BMI >30 kg/m2 in adults or 
weight >97th centile in children, Subcutaneous Ossifications (SO), Mental Retardation (MR). Age 1 refers to the age at molecular diagnosis, while age 2 is the one at 
clinical diagnosis. PTH and TSH levels refer to the ones at clinical diagnosis, normal values: 10-65 pg/mL for PTH and 0.2-4.0 mUI/L for TSH (unknown levels for 
patients 4&5 in whom a neonatal diagnosis of primary hypothyroidism was made).  
 
SUPPLEMENTARY INFORMATION 
 
1. DETAILED DESCRIPTION OF MOLECULAR BIOLOGY TECHNIQUES 
APPLIED TO UNRAVEL AND CHARACTERIZE GNAS STRUCTURAL 
REARRANGEMENTS IN OUR SERIES 
 
1.1 GNAS locus MS-MLPA analysis 
 
Dosage of allele segments and methylation analyses of GNAS locus were carried out by 
MS-MLPA using the SALSA MLPA ME031 GNAS probemix (MRC-Holland, 
Amsterdam, The Netherlands) and ABI3130xl and ABI3500 Genetic Analyzers 
(Perkin-Elmer Corp.), as previously described (S1, S2). Data analysis was performed 
using GeneMapper software (Applied Biosystems, Foster City, CA) and Coffalyser v9.4 
(MRC-Holland, Amsterdam, The Netherlands). A probe ratio below 0.7 for different 
consecutive probes was considered suggestive of a heterozygous deletion. 
 
1.2 Genome-wide SNParray 
 
An Illumina Human660W-Quad BeadChip was run for patients #1 and #5. This array 
includes 657,366 markers distributed evenly across the genome, with 14,854 markers 
located on chromosome 20. Images were analyzed using the Chromosome Viewer tool 
contained in Genome Studio (Illumina, San Diego, CA, USA). 
 
1.3 Custom CGHarray 
 
Two independent custom aCGH have been used: 
 
Patients #6 and #7: A custom CGH array was designed to cover by high density the 
GNAS locus and 15 additional genes localized on chromosome 1, 3, 6, 7, 9, 12, 16, 17, 
19, 20, 22 and X (15K oligo array, Agilent Technologies, CA, USA; design ID33306). 
The GNAS locus (chr20: g.57414773-g.57486255) was covered by a total of 476 
probes, and STX16 gene (exon 3 and 4) by 19 probes (i.e a density of ~ one 60 mer 
oligonucleotide CGH probe every 150-bp).  1 000-kb flanking 3’ and 5’ regions at the 
boundary of the locus were covered by a density of ~ one probe every 4000-bp.  On 
each slide, samples comprised DNA from one control used as reference DNA (identical 
on each slide), and from 7 patients affected by one pathology putatively associated with 
a defect in one of the selected genes; therefore samples from non-affected patients for a 
specific gene served as controls for that gene. Two to four patients affected with PHP 
were studied on each slide. Array design was validated by analysing samples with 
previously identified deletion in each gene. Data were analyzed using Feature 
Extraction V.91.1 and CGH analysis V3.4.27. 
Patients #5 and #6: Whole genome analysis was conducted using a custom chromosome 
20 focused 4x44k oligonucleotide human array-CGH (AMADID 49562, Agilent 
Technologies, Santa Clara, CA), following manufacturer’s protocol. Custom array 
covered chr20: g.57,200,000-g.57,500,000 with one probe each 200-bp, whole 
chromosome 20 with one probe each 2-kb and a backbone with one probe each 300-kb. 
Commercial healthy male DNA (Promega Biotech, Madison, WI) was used as 
hybridization control. Microarray data was extracted and visualized using Feature 
Extraction software v10.7 and Agilent Genomic Workbench v5.0 (Agilent 
Technologies). Copy number altered regions were detected using ADM-2 (set as 6) 
statistic provided by DNA Analytics, with a minimum number of 5 consecutive probes. 
Genomic build NCBI37 (Hg19) was used for the experiments. 
 
1.4 Boundaries’ delimitation 
 
As a first step toward the delimitation of deletions, different methods for 
semiquantitative amplifications were used.  
Semiquantitative PCR (sq-PCR) 
Semiquantitative amplification of specific sequences (about 100-bp length) surrounding 
the region found deleted by MS-MLPA was performed (primers available upon 
request). Briefly, serial dilutions of wild-type DNA were amplified by non-saturated 
PCR (20 cycles) together with patients DNA and, after agarose electrophoresis, were 
analyzed by densitometric scanning of photographs of gels with ImageJ software. 
Alternatively, semiquantitative multiplex PCR of short fluorescent fragments (QMPSF) 
was employed. Firstly, we designed diverse PCR fragments for each flanking region. In 
the 5’flanking region the reverse primer was marked with fluorescence, whilst in the 
3’flanking region the marked primer was forward. These PCRs were performed vs. a 
known 2 copies region of the genome (as control region) to get a relative 
semiquantitative PCR (stopped at exponential phase). After the multiplex reaction, the 
DNA fragments were separated on an ABI3500 Genetic Analyzer and analyzed using 
GeneMapper software (Applied Biosystems). 
To calculate allele dosage we used the numerical sample-to-control comparison. We 
calculated numerical normalized ratios (R) using the formula: R=(peak intensityamplicon x 
sample/peak intensityamplicon x control)/(peak intensityamplicon ref sample/peak intensityamplicon ref 
control). An R value close to 0.5 (0.4–0.6) represented a 2-fold reduction. As a result we 
found regions that were located inside the deletion (PCR relative ratio~0.5) and other 
regions that were located outside the deletion (PCR relative ratio~1). The objective was 
to approach as much as possible to the deletion, for the purpose of obtaining a large 
PCR of the deleted allele and sequences it to identify the breakpoints. This final PCR 
was run with the nearest to the deletion forward unlabeled primer of the 5’falnking 
region (in which two copies were observed) and the nearest to the deletion unlabeled 
reverse of the 3’flanking region (conditions and primers available upon request). 
Then, to locate breakpoints at nucleotide level, long range PCRs with primers flanking 
deleted sequences and a highly performing proofreading polymerase, LA Taq DNA 
Polymerase (Takara Bio Inc., Otsu, Japan), were performed (conditions and primers 
available upon request).  
Finally, amplicons from deleted alleles were excised from agarose gel after 
electrophoretic separation, extracted with the MinElute Gel Extraction kit (Qiagen, 
Hilden, Germany) and sequenced. 
 
1.5 Parental origin of deletions 
 
When possible, deletion’s parental origin was determined either by long-PCR crossing 
the boundaries, by microsatellite markers analysis or deduced by the methylation status 
obtained by MS-MLPA. Three microsatellites were genotyped by migration of the 
fluorescent- labelled PCR products on a 3130xl Genetic Analyzer (AppliedBiosystems), 
a 18AC repeat (g.58,304,592-g.58,304,928) localized at the 5' end of the GNAS locus, a 
28AC repeat (g.58,439,667-g.58,440,096) within the GNAS locus, and a 19AC repeat 
(g.58,529,668-g.58,530,005) localized at the 3' end of the GNAS locus. 
 
1.6 In silico analysis of breakpoint regions  
 
Breakpoint regions and junction fragments were subjected to an extensive bioinformatic 
analysis to assess the involvement of the genomic architecture in the origin of the 
deletions as previously described (S3). 
 
2. DETAILED DESCRIPTION OF NOVEL GNAS STRUCTURAL 
REARRANGEMENTS IDENTIFIED IN OUR SERIES  
 
2.1 Short deletions 
 
Defects detected in patients #2, #3, #4 and #7 were short GNAS deletions, affecting only 
one to seven Gsα-coding exons. The methylation analysis confirmed the absence of 
imprinting defects for patients #2, #4 and #7. 
 
MS-MLPA investigation of sisters #2a and #2b led to the hypothesis of a deletion 
encompassing, at least GNAS exons from 7 to 13. Breakpoint characterization and 
parent’s analysis confirmed a maternally-inherited interstitial deletion of 5,842-bp at 
genomic location g.57,482,794_57,488,635, according to the Genome Reference 
Consortium Human Build 37 (GRCh37) (Figure 1A). Their mother (#2m) presented 
only short stature with normal serum calcium, phosphorous and PTH levels. 
 
In patient #4, MS-MLPA revealed a heterozygous deletion within GNAS exon 13 and 
subsequent analysis showed a 106-bp de novo interstitial deletion including part of 
intron 12 and of exon 13 (genomic location g.57,485,642_57,485,748) (Figure 1A). 
 
According to custom made CGH analysis, patient #7a presented a heterozygous deletion 
of about 6200-bp extending from intron 2 (first 5'deleted probe at 57,475,366) to intron 
5 (last 3'deleted probe at 57,481,550), and thus leading to the partial deletion of introns 
2 and 5, and the entire sequence of exons 3, 4 and 5, and introns 3 and 4. MS-MLPA 
analysis confirmed the deletion. Fine delimitation allowed the identification of a 6,431-
bp deletion ranging from locations g.57,475,484 to g.57,481,914. Within the deletion a 
16-bp insertion of unknown genetic origin was identified (Figure 1A). The same genetic 
defect was present in the mother of the patient (#7b). 
 
In patient #3 we observed a deletion encompassing exon A/B to exon 1 revealing a 
methylation defect limited to the A/B DMR, an imprinting error classically associated 
with the autosomal dominant inherited form of PHP1B. This deletion could not be 
delimited at the nucleotide level due to lack of further material, but available data 
allowed to determine a deletion extension range between 2,793 and 6,928-bp 
[g.(57,463,738_57,464,100)_(57,466,893_57,470,666)del] (Figure 1A). Parents were 
not available. 
 
2.2 Long deletions 
 
Deletions found in patients #1, #5 and #6 comprised the entire GNAS locus. 
Methylation analysis of  patients #1 and #5 displayed a pattern of loss of imprinting 
(LoI) similar to that detected in sporadic PHP1B cases (loss of methylation at AS, XL 
and A/B DMRs and gain of methylation at NESP DMR), indicating that the maternal 
allele was ablated. On the contrary, patient #6 presented the opposite methylation 
pattern, as the deleted allele was the paternal one. 
 
In patient #1, SNP array followed by quantitative PCR and long-PCR revealed the 
presence of an heterozygous maternally inherited deletion of 2.6-Mb, extending from 
g.57,224,346 to g.59,795,557 (Figure 1B). The deletion encompassed STX16, NPEPL1, 
GNAS-AS1, GNAS, NELFCD, CTSZ, TUBB1, SLMO2, ATP5E, ZNF831, EDN3, 
PHACTR3, SYCP2, PPP1R3D and CDH26 genes. The mother was clinically 
asymptomatic. 
 
A similar approach was performed for patient #5. The statistical deletion obtained after 
SNP-array and aCGH extended from g.56,987,684 to g.59,350,455 (size 2,362,772-bp), 
though data was also compatible with a deletion beginning at 56,982,790 bp (size 
2,367,666-bp). Exact breakpoints however could not be determined as it couldn’t be 
amplified and sequenced (Figure 1B). Putatively involved genes are VAPB, APCDD1L, 
APCDD1L-AS1, STX16, NPEPL1, GNAS-AS1, GNAS, NELFCD, CTSZ, TUBB1, 
SLMO2, ATP5E, ZNF831, EDN3, PHACTR3, SYCP2, PPP1R3D and CDH26. The 
deletion was present in the unaffected mother and the maternal grandfather. 
 
In patient #6 custom made CGH analysis led to the identification of a 1.7-Mb de novo 
deletion extending from g.55,926,306 to g.57,675,816 (Figure 1B). Microsatellite 
markers genotyping of the proband and her parents confirmed the paternal origin of the 
deletion. The deletion encompassed MTRNR2L3, RBM38, CTCFL, PCK1, ZBP1, 
PMEPA1, PPP4R1L, RAB22A, VAPB, APCDD1L, APCDD1L-AS1, STX16, NPEPL1, 
GNAS-AS1, GNAS, NELFCD, CTSZ, TUBB1, SLMO2 and ATP5E genes, and putatively 
the 3'-end of RAE1. 
3. In silico analysis of breakpoint regions 
 
In total, 2 of 8 sequence motifs were present. An immunoglobulin heavy chain class 
switch repeat in the proximal region of patient #1 and deletion hotspot consensus 
sequence, at the distal region of patient #4. The other breakpoint regions did not contain 
any known sequence motif.  
The analysis of the AT-percentages at sequences located 125-bp down- and upstream of 
proximal and distal breakpoints showed AT-enriched regions (≥75%) on both 
breakpoints for patient #2.  
The Repeat Masker track in the UCSC genome browser was used to analyze the 
presence of known repetitive elements intersecting breakpoints. A repetitive element 
was found at 4 of 5 breakpoints (80%), all of them belonging to the same class, 
consisting of three Alu- Alu and one LINE2-LINE2 combinations. In these cases, a 
Blast2 analysis was performed to determine the percentage of sequence identity 
between the repetitive elements. The highest percentage of sequence identity was 
observed between Alu elements in patient #2 (88%), while the lowest between LINE2 
elements in patient #1 with only 13-bp complementarity in both LINEs.  
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Supplementary Table 1: Brief summary of the techniques employed in the analysis of 
each patient. 
 
 
Patient MS-MLPA SNP array Custom aCGH 15k Custom aCGH 44k Sq-PCR QMPSF Long range PCR
1 a a a a
2 a a a
3 a
4 a a a
5 a a a a
6 a a a
7 a a
 Supplementary Table 2: Overview of the characteristic of the deletion breakpoints. The positions of the proximal and distal breakpoints or 
breakpoint regions were given according to the UCSC Human Genome Browser assembly from February 2009 (GRCh37/hg19). Breakpoint 
sequences are given, including 25 bp down-and upstream from the breakpoints or breakpoint regions if homologous sequences (highlighted in 
bold) were present at the breakpoint junctions. Down-and upstream borders of the deleted sequences are indicated in small characters. 
Alternating purine-pyrimidine sequences are underlined. Finally, DNA sequence motifs associated with deletions are marked in grey, while the 
motif sequence, repetitive elements identified, the identity between the repetitive elements and the plausible molecular mechanisms for each 
deletion can be found in the last columns. NHEJ (Non-homologous end joining). ARMD (Alu recombination-mediated deletion). 
 
 
 
                         
Patient 
Start     
(hg19) 
End     
(hg19) 
Size (bp) Breakpoint Sequences 
Micro-
homolo
gy 
Repetitive 
elements 
(proximal region) 
Sequence 
Motifs 
(proximal 
region) 
Repetitive 
elements 
(distal region) 
Sequence 
Motifs 
(distal 
region) 
Sequence 
identity 
between 
repetitive 
elements 
Putative 
molecular 
mechanism 
1 57224346 59795557 2571212 
Proximal:                 
ATCACGTTCTAGCCTGGGGGAGAGCgccaggaaaagtaaacaggtccccc                  
Distal:                       
tctgacaaatattttttaagcacttGCTATGTTCTAGGGACTGTAACAAG 
2 bp
(GC) 
L2c TGGGG L2a - 
13 bp 
palindromic 
sequence 
Replicative / 
Classical NHEJ 
2a&2b 57482794 57488635 5842 
Proximal:                
AAGGAAACTCAGAGAAAAAGAGAACaacgcagcttaaaacttttaaaatg               
Distal:                
atttttttaatctgaatgcctgtaaTCCCAGCACTTTGGGAGGCCGAGGT 
- AluSg4 - AluY - 88% ARMD 
4 57485643 57485747 106 
Proximal:                                 
TTTTGTTTTCATATGACATCAGAGGctggctgacagccgtccctggtagg               
Distal:                   
tgtttgtgcccgcagaggatcagcaCTGCCAGTGGAGATGGGCGTCACTA 
3 bp
(CTG) 
- - - TGGAGA   
 Replicative / 
Classical NHEJ 
6 55926306 57675816 1749511 
Proximal:                      
AGGAAGTGGCTCCAGGGCGCACGCGcgttgtttccgcggtagtcagggca                 
Distal:                       
cctcaggtgatccactcacctcagcTTCCCAAAGTGCTGGAATTACAGGC 
- AluSq2 - AluSx - 85% ARMD 
7 57475484 57481914 
6431 + 16pb 
insertion 
Proximal:              
AGCAATCCCTGTATCTCGCGTCTGTcttctgtcttccttcctttgtctgt                 
Distal:                                                                                                  
tgtaaagatatcttctgtttgttgaTGC TGCAGAAATGCACAAAGCAGTC 
- AluSx - AluSg4 - 84% 
Classical NHEJ / 
ARMD 
Supplementary figure 1: Schematic representation of reported deleted regions and 
genes in the long arm of chromosome 20. The common deleted  region in patients with 
a rearrangement affecting the paternal allele includes genes from RAE1 to ATP5E. 
Deletions affecting the maternal allele are smaller than paternal ones, and encompasses 
genes from STX16 to CDH26. The smallest region of overlap (SRO) among all 
described multigenic deletions of 20q ranges from STX16 to ATP5E. 
